Compare · NEOG vs ORKA
NEOG vs ORKA
Side-by-side comparison of Neogen Corporation (NEOG) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 2.7x NEOG ($2.54B).
- Both names hit the wire about 11 times in the past 4 weeks.
- ORKA has more recent analyst coverage (11 ratings vs 5 for NEOG).
- Company
- Neogen Corporation
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $2.54B
- $6.74B
- 1M return
- -
- +12.94%
- 1Y return
- -
- +588.78%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 11
- 11
- Recent ratings
- 5
- 11
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest NEOG
- SEC Form DEFA14A filed by Neogen Corporation
- SEC Form DEF 14A filed by Neogen Corporation
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,365 units of Restricted Stock Units, decreasing direct ownership by 7% to 29,331 units (SEC Form 4)
- CEO Nassif Mikheal covered exercise/tax liability with 20,397 units of Restricted Stock Units, decreasing direct ownership by 44% to 25,655 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick was granted 8,584 units of Restricted Stock Units, increasing direct ownership by 36% to 32,155 units (SEC Form 4)
- Senior Vice President Ranalli Tamara A. was granted 25,751 shares (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 38,627 shares (SEC Form 4)
- CFO Riggsbee Richard Bryan was granted 51,502 shares (SEC Form 4)
- CEO Nassif Mikheal was granted 141,631 shares (SEC Form 4)
- Neogen Corporation filed SEC Form 8-K: Leadership Update
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update